



**Rheumatology Enrollment Form**

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

<b>PATIENT INFORMATION</b>	Patient Name: _____	<b>PRESCRIBER INFORMATION</b>	Prescriber's Name: _____
	Address: _____		State License #: _____ NPI #: _____
	City: _____ State: _____ Zip: _____		DEA #: _____
	Primary Phone: _____ DOB: _____		Group or Hospital: _____
	Alternate Phone: _____ Gender: <input type="checkbox"/> Male <input type="checkbox"/> Female		Address: _____
	Email: _____		City: _____ State: _____ Zip: _____
	Last Four of SS #: _____ Primary Language: _____		Phone: _____ Fax: _____
	Height: _____ Weight: _____		Contact Person: _____ Phone: _____

**INSURANCE INFORMATION: PLEASE FAX A COPY OF THE PRESCRIPTION & INSURANCE CARDS WITH THIS FORM, IF AVAILABLE (FRONT & BACK)**

<b>CLINICAL</b>	Need By Date: _____	Ship to: <input type="checkbox"/> Patient <input type="checkbox"/> Physician <input type="checkbox"/> Other: _____	
	Date of Diagnosis: _____	Diagnosis: <input type="checkbox"/> M06.9 Rheumatoid Arthritis <input type="checkbox"/> M45.9 Ankylosing Spondylitis <input type="checkbox"/> L40.54 Psoriatic Arthritis <input type="checkbox"/> M08 Juvenile Idiopathic Arthritis	
		<input type="checkbox"/> Non-radiographic Axial Spondyloarthritis <input type="checkbox"/> New diagnosis <input type="checkbox"/> Other: _____	
	Prior Medications: <input type="checkbox"/> Acetaminophen, ibuprofen, naproxen, aspirin <input type="checkbox"/> Humira <input type="checkbox"/> Enbrel <input type="checkbox"/> Methotrexate <input type="checkbox"/> Corticosteroids <input type="checkbox"/> Hydroxychloroquine	<input type="checkbox"/> Leflunomide <input type="checkbox"/> Sulfasalazine <input type="checkbox"/> Other meds tried: _____	
	Current Medications: _____	Is the patient also taking methotrexate? <input type="checkbox"/> Yes <input type="checkbox"/> No	
	Allergies: _____	Is the patient new to therapy? <input type="checkbox"/> Yes <input type="checkbox"/> No	
Has patient had positive TB test? <input type="checkbox"/> Yes <input type="checkbox"/> No	If yes, date of last chest x-ray: _____	Is a starter dose needed? <input type="checkbox"/> Yes <input type="checkbox"/> No	

	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFIL
<b>PRESCRIPTION INFORMATION</b>	<input type="checkbox"/> Cimzia®	<input type="checkbox"/> Starter Kit (200 mg Prefilled Syringes) <input type="checkbox"/> 200mg/ml Prefilled Syringe <input type="checkbox"/> 200mg Vial	<input type="checkbox"/> 400mg Sub-Q at weeks 0, 2, and 4 <input type="checkbox"/> 400mg Sub-Q every 4 weeks <input type="checkbox"/> 200mg Sub-Q every 2 weeks <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 Kit = 6 x 200 mg/mL PFS <input type="checkbox"/> 1 Carton = 2 x 200 mg/mL PFS <input type="checkbox"/> 1 Carton = 2 x 200 mg Vials	0 _____ _____
	<input type="checkbox"/> Enbrel®	<input type="checkbox"/> 50mg/ml Sureclick™ <input type="checkbox"/> 50mg/ml Prefilled Syringe <input type="checkbox"/> 25mg/0.5ml Prefilled Syringe <input type="checkbox"/> 25mg Vial	<input type="checkbox"/> Inject 50mg Sub-Q ONCE a week <input type="checkbox"/> Inject 25mg Sub-Q TWICE a week (72-96 hours apart). <input type="checkbox"/> Other: _____	<input type="checkbox"/> 4 <input type="checkbox"/> 8	_____ _____
	<input type="checkbox"/> Humira® (Citrate-free)	<input type="checkbox"/> 40mg/0.4mL CF Pen <input type="checkbox"/> 40mg/0.4mL CF Prefilled Syringe <input type="checkbox"/> 20mg/0.2mL CF Prefilled Syringe <input type="checkbox"/> 10mg/0.1mL CF Prefilled Syringe	<input type="checkbox"/> Inject 40mg Sub-Q every OTHER week <input type="checkbox"/> Inject 40mg Sub-Q every week <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 pens/PFS <input type="checkbox"/> 4 pens/PFS	_____ _____
	<input type="checkbox"/> Humira®	<input type="checkbox"/> 40mg/0.8mL Pen <input type="checkbox"/> 40mg/0.8mL Prefilled Syringe	<input type="checkbox"/> Inject 40mg Sub-Q every OTHER week <input type="checkbox"/> Inject 40mg Sub-Q every week <input type="checkbox"/> Other: _____	<input type="checkbox"/> 2 pens/PFS <input type="checkbox"/> 4 pens/PFS	_____ _____
	<input type="checkbox"/> Actemra®	<input type="checkbox"/> 162mg/0.9mL Prefilled Syringe <input type="checkbox"/> 162mg/0.9mL ACTPen™	<input type="checkbox"/> Inject 162mg Sub-Q every OTHER week <input type="checkbox"/> Inject 162mg Sub-Q every week	<input type="checkbox"/> 2 <input type="checkbox"/> 4	_____ _____
	<input type="checkbox"/> Orencia®	<input type="checkbox"/> 250mg Vial (IV use only) <input type="checkbox"/> 125 mg Prefilled Syringe <input type="checkbox"/> 125 mg Autoinjector	<input type="checkbox"/> 10mg/kg IV x 1 dose, then 125mg Sub-Q weekly, start within 24hrs of IV dose <input type="checkbox"/> Other: _____ <input type="checkbox"/> 125mg Sub-Q ONCE a week <input type="checkbox"/> 125mg Sub-Q ONCE a week	<input type="checkbox"/> 1 Vial <input type="checkbox"/> 4 Syringes <input type="checkbox"/> 4 Pens	_____ _____ _____
	<input type="checkbox"/> Simponi®	<input type="checkbox"/> 50mg/0.5ml Autoinjector <input type="checkbox"/> 50mg/0.5ml Prefilled Syringe <input type="checkbox"/> 100mg/ml Syringe <input type="checkbox"/> 100mg/ml Autoinjector	<input type="checkbox"/> Inject 1 dose Sub-Q once monthly <input type="checkbox"/> Other: _____	<input type="checkbox"/> 1 (one)	_____ _____
	<input type="checkbox"/> Cosentyx®	<input type="checkbox"/> 150mg/mL Prefilled Syringe <input type="checkbox"/> 150mg/mL Pen	<input type="checkbox"/> Starter Dose: Inject 300mg Sub-Q Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29 <input type="checkbox"/> Starter dose: Inject 150mg Sub-Q Day 1, Day 8, Day 15, Day 22, and then every 4 weeks starting on Day 29 <input type="checkbox"/> Maintenance Dose: Inject the contents of 300mg Sub-Q starting Day 29 and then every 4 weeks thereafter <input type="checkbox"/> Maintenance Dose: Inject the contents of 150mg Sub-Q starting Day 29 and then every 4 weeks thereafter	<input type="checkbox"/> 8 <input type="checkbox"/> 4 <input type="checkbox"/> 2 <input type="checkbox"/> 2	0 0 _____ _____
	<input type="checkbox"/> Taltz®	<input type="checkbox"/> 80mg/mL Autoinjector <input type="checkbox"/> 80 mg/mL Prefilled Syringe	<input type="checkbox"/> Starter Dose: Inject 160 mg Sub-Q Day 1, followed by 80 mg every 4 weeks starting on Day 29 <input type="checkbox"/> Maintenance Dose: Inject 80 mg Sub-Q starting Day 29 and then every 4 weeks thereafter	<input type="checkbox"/> 2 <input type="checkbox"/> 1	0 _____

PHYSICIAN SIGNATURE REQUIRED

X _____	X _____
PRODUCT SUBSTITUTION PERMITTED (Date)	DISPENSE AS WRITTEN (Date)

Ancillary supplies and kits will be provided as needed for administration.

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 45050562 (1/20)



**Rheumatology Enrollment Form**

Phone: 855-425-4085

Fax: 855-425-4096

ardonhealth.com

PRESCRIPTION INFORMATION	MEDICATION	DOSE/STRENGTH	DIRECTIONS	QUANTITY	REFILL	
	<input type="checkbox"/> Stelara®	<input type="checkbox"/> 45mg/0.5mL Prefilled Syringe <input type="checkbox"/> 90mg/1mL Prefilled Syringe	<input type="checkbox"/> Starter Dose: Inject 1 prefilled syringe Sub-Q Day 1 <input type="checkbox"/> Maintenance Dose: Inject the contents of 1 prefilled syringe Sub-Q starting Day 29 & every 12 weeks thereafter	<input type="checkbox"/> 1 PFS <input type="checkbox"/> 1 PFS	0 —	
	<input type="checkbox"/> Xeljanz®	<input type="checkbox"/> 5mg Tab <input type="checkbox"/> 11mg XR Tab	<input type="checkbox"/> Take one 5mg tablet PO twice daily <input type="checkbox"/> Take one 11mg XR tablet PO once daily <input type="checkbox"/> Other: _____	<input type="checkbox"/> 60 <input type="checkbox"/> 30	—	
	<input type="checkbox"/> Otezla®	<input type="checkbox"/> Otezla Starter Kit <input type="checkbox"/> Otezla 30mg Tablet	<input type="checkbox"/> Starter Dose: Take as directed per package instructions <input type="checkbox"/> Maintenance Dose: Take 1 tablet by mouth twice daily	<input type="checkbox"/> 55 <input type="checkbox"/> 60	0 —	
	<input type="checkbox"/> Remicade®	<input type="checkbox"/> Remicade 100mg vial	<input type="checkbox"/> Induction: Infuse _____mg IV at weeks 0, 2, and 6 <input type="checkbox"/> Maintenance: Infuse _____mg IV at every 8 weeks	<input type="checkbox"/> _____ # Vial(s)	—	
	<input type="checkbox"/> Kevzara®	<input type="checkbox"/> 150mg/1.14ml Prefilled Syringe <input type="checkbox"/> 200mg/1.14ml Prefilled Syringe	<input type="checkbox"/> Inject 150mg Sub-Q every OTHER week <input type="checkbox"/> Inject 200mg Sub-Q every OTHER week	<input type="checkbox"/> 2	—	
	<input type="checkbox"/> Olumiant®	<input type="checkbox"/> 1mg Tab <input type="checkbox"/> 2mg Tab	<input type="checkbox"/> Take one 1mg tablet PO once daily <input type="checkbox"/> Take one 2mg tablet PO once daily	<input type="checkbox"/> 30	—	
	<input type="checkbox"/> Rinvoq®	<input type="checkbox"/> 15 mg XR Tab	<input type="checkbox"/> Take one 15mg tablet PO once daily	<input type="checkbox"/> 30	—	
	<input checked="" type="checkbox"/> PRODUCT SUBSTITUTION PERMITTED (Date) _____ Ancillary supplies and kits will be provided as needed for administration.			<input checked="" type="checkbox"/> DISPENSE AS WRITTEN (Date) _____		

Date Needed: \_\_\_\_\_ Medication Start Date: \_\_\_\_\_

The information included in this FAX is intended for the sole use of the individual to whom it is addressed and may contain information that is privileged, confidential and exempt from disclosure under applicable law. If you are not the intended addressee, nor authorized to receive for the intended addressee, you are hereby notified that you may not use, copy, disclose or distribute this information. If you have received this FAX in error, please contact the sender and destroy the entire document. 45050562 (1/20)

This prescription is valid only if transmitted by facsimile machine by a licensed provider